Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab

Copyright 2014, SLACK Incorporated.

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 45(2014), 6 vom: 21. Nov., Seite 534-41
1. Verfasser: Byon, Ik Soo (VerfasserIn)
Weitere Verfasser: Kwon, Han Jo, Kim, Sung Il, Shin, Min Kyu, Park, Sung Who, Lee, Ji Eun
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2014
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Coloring Agents Photosensitizing Agents Porphyrins VEGFA protein, human Vascular Endothelial Growth Factor A Verteporfin 0X9PA28K43 mehr... Indocyanine Green IX6J1063HV Ranibizumab ZL1R02VT79
LEADER 01000caa a22002652c 4500
001 NLM243791461
003 DE-627
005 20250217185729.0
007 cr uuu---uuuuu
008 231224s2014 xx |||||o 00| ||eng c
024 7 |a 10.3928/23258160-20141118-08  |2 doi 
028 5 2 |a pubmed25n0812.xml 
035 |a (DE-627)NLM243791461 
035 |a (NLM)25423633 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Byon, Ik Soo  |e verfasserin  |4 aut 
245 1 0 |a Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab 
264 1 |c 2014 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 11.05.2015 
500 |a Date Revised 02.12.2018 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Copyright 2014, SLACK Incorporated. 
520 |a BACKGROUND AND OBJECTIVE: To evaluate the effect of reduced-fluence photodynamic therapy (PDT) on polypoidal choroidal vasculopathy (PCV) unresponsive to intravitreal ranibizumab 
520 |a PATIENTS AND METHODS: Patients with PCV unresponsive to ranibizumab administered 3 months consecutively who then received reduced-fluence PDT were retrospectively surveyed. Nonresponders were defined as patients having no reduction in intraretinal and/or subretinal fluid after 3 consecutive treatments 
520 |a RESULTS: In total, 22 of 104 eyes (21.2%) were non-responders, and 16 of 22 nonresponders received reduced-fluence PDT. Nine eyes achieved complete fluid resolution, and six had reduced but persistent fluid. In one eye, fluid persisted at 6 months despite an additional anti-vascular endothelial growth factor (anti-VEGF) injection after reduced-fluence PDT. Mean macular thickness decreased significantly at 3 and 6 months after PDT, but the mean visual acuity was worse than baseline 
520 |a CONCLUSION: Reduced-fluence PDT in nonresponders gradually decreased intraretinal and/or subretinal fluid over several months but did not maintain visual acuity 
650 4 |a Journal Article 
650 7 |a Angiogenesis Inhibitors  |2 NLM 
650 7 |a Antibodies, Monoclonal, Humanized  |2 NLM 
650 7 |a Coloring Agents  |2 NLM 
650 7 |a Photosensitizing Agents  |2 NLM 
650 7 |a Porphyrins  |2 NLM 
650 7 |a VEGFA protein, human  |2 NLM 
650 7 |a Vascular Endothelial Growth Factor A  |2 NLM 
650 7 |a Verteporfin  |2 NLM 
650 7 |a 0X9PA28K43  |2 NLM 
650 7 |a Indocyanine Green  |2 NLM 
650 7 |a IX6J1063HV  |2 NLM 
650 7 |a Ranibizumab  |2 NLM 
650 7 |a ZL1R02VT79  |2 NLM 
700 1 |a Kwon, Han Jo  |e verfasserin  |4 aut 
700 1 |a Kim, Sung Il  |e verfasserin  |4 aut 
700 1 |a Shin, Min Kyu  |e verfasserin  |4 aut 
700 1 |a Park, Sung Who  |e verfasserin  |4 aut 
700 1 |a Lee, Ji Eun  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Ophthalmic surgery, lasers & imaging retina  |d 2013  |g 45(2014), 6 vom: 21. Nov., Seite 534-41  |w (DE-627)NLM224956647  |x 2325-8179  |7 nnas 
773 1 8 |g volume:45  |g year:2014  |g number:6  |g day:21  |g month:11  |g pages:534-41 
856 4 0 |u http://dx.doi.org/10.3928/23258160-20141118-08  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_40 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_90 
912 |a GBV_ILN_91 
912 |a GBV_ILN_130 
912 |a GBV_ILN_135 
912 |a GBV_ILN_136 
912 |a GBV_ILN_151 
912 |a GBV_ILN_181 
912 |a GBV_ILN_203 
912 |a GBV_ILN_217 
912 |a GBV_ILN_235 
912 |a GBV_ILN_289 
912 |a GBV_ILN_294 
912 |a GBV_ILN_297 
912 |a GBV_ILN_350 
912 |a GBV_ILN_352 
912 |a GBV_ILN_674 
912 |a GBV_ILN_676 
912 |a GBV_ILN_688 
912 |a GBV_ILN_698 
912 |a GBV_ILN_721 
912 |a GBV_ILN_737 
912 |a GBV_ILN_791 
912 |a GBV_ILN_812 
912 |a GBV_ILN_1127 
951 |a AR 
952 |d 45  |j 2014  |e 6  |b 21  |c 11  |h 534-41